Medigene AG Secures Chinese Patent for TCR-T Therapy Targeting NY-ESO-1 and LAGE 1a
Medigene AG (ETR: MDG1), a biopharmaceutical company based in Germany, has announced that it has...
Clinical trial filings
AIM Vaccine Submits Pre-IND Applications for mRNA Vaccines Targeting RSV and Herpes Zoster to NMPA
AIM Vaccine Co., Ltd (HKG: 6660), a biopharmaceutical company based in China, has announced the...
Mabwell’s 9MW2821 ADC for Triple Negative Breast Cancer Accepted for Review by NMPA
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
InnoCare Pharma Receives IND Approval in China for BCL2 Inhibitor Combo Therapy
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has announced that it has...
Sino-US Laekna’s LAE102 Clinical Trial Filing Accepted for Review in Obesity and Metabolic Disorders
Sino-US Laekna (HKG: 2105) has announced that its clinical trial application for LAE102, an antibody...
Phanes Therapeutics’ First-in-Class BsAb PT217 Accepted for Review by China’s CDE
Sino-US biotechnology company Phanes Therapeutics Inc. has announced that the Investigational New Drug (IND) filing...
Everest Medicines Secures IND Review for Zetomipzomib in China
Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for zetomipzomib...
Acotec Secures FDA IDE Approval for AcoArt Litos Paclitaxel-Coated Balloon Catheter
Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received Investigational Device Exemption (IDE)...
SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA
SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National...
Sirius Therapeutics Pursues First-in-Human Trial for SRSD107 in Australia
Sino-US biotech Sirius Therapeutics has announced its pursuit of Investigational New Drug (IND) approval in...
Wyze Biotech’s RJMty19 Injection Accepted for CDE Review for r/r B-Cell NHL
Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has announced...
Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...
Shanghai Fudan-Zhangjiang’s ADC FZ-AD005 Accepted for NMPA Review in Advanced Solid Tumors
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the National...
Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
Hainan Poly Pharm’s PL002 Accepted for FDA Review for Liver Cancer Surgery
China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational...
Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration...
Sino Biopharmaceutical Submits IND Application for AT2R Antagonist TRD205 to FDA
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has announced the filing of...
Betta Pharmaceuticals’ CFT8919 Accepted for Review by China’s NMPA for EGFR L858R Solid Tumors
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a China-based pharmaceutical company, has announced that the National...
Hybio Pharmaceutical’s Semaglutide Clinical Trial Filing Accepted by China’s NMPA
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...
Jointown Medical’s COVID-19 Drug Candidate SHEN211 Accepted for Review by NMPA
China-based Jointown Medical Devices Group Co., Ltd (SHA: 600998) has announced that its clinical trial...